Microemulsion Formulations Comprising Particular Substance P Antagonists

ABSTRACT

The present invention relates to dispersible pharmaceutical compositions in which the active agent is a substance P antagonist, in particular a 5-aryl-4(R)-arylcarbonylamino-pent-2-enoic acid amide, that is useful for the treatment and prevention of respiratory diseases including asthma and chronic obstructive pulmonary disease, bowel disorders including irritable bowel syndrome (IBS), urinary incontinence, and cough.

The present invention relates to novel pharmaceutical compositions in which the active agent is a substance P antagonist, in particular a S-aryl-4(R)-arylcarbonylamino-pent-2-enoic acid amide, that is useful for the treatment and prevention of respiratory diseases including asthma and chronic obstructive pulmonary disease, bowel disorders including irritable bowel syndrome (IBS), urinary incontinence, and cough.

5-aryl-4(R)-arylcarbonylamino-pent-2-enoic acid amide substance P antagonists are a class of compounds described in international patent application WO 98/07694, the contents of which publication is incorporated herein by reference.

5-aryl-4(R)-arylcarbonylamino-pent-2-enoic acid amide substance P antagonists, such as those disclosed in WO 98/07694, present highly specific difficulties in relation to administration generally and galenic compositions in particular, including in particular problems of drug bioavailability and variability in inter- and intra-patient dose response, necessitating development of a non-conventional dosage form.

In accordance with the present invention it has now surprisingly been found that stable pharmaceutical compositions with 5-aryl-4(R)-arylcarbonylamino-pent-2-enoic acid amide substance P antagonists, having particularly interesting bioavailability characteristics and reduced variability in inter- and intra-subject bioavailability parameters, are obtainable. These novel compositions have been found to meet or substantially reduce the difficulties encountered previously. It has been shown that the compositions of the invention may enable effective dosaging with concomitant enhancement of bioavailability as well as reduced variability of absorption/bioavailability levels for and between individual patients. Thus, the invention may achieve effective therapy with tolerable dosage levels of such S-aryl-4(R)-arylcarbonylamino-pent-2-enoic acid amide substance P antagonists, and may permit closer standardization and optimization of daily dosage requirements for each individual. Consequently, occurrence of potential undesirable side-effects is diminished and overall cost of therapy may be reduced.

In a first aspect the present invention provides a spontaneously dispersible pharmaceutical composition comprising a 5-aryl-4(R)-arylcarbonylamino-pent-2-enoic acid amide substance P antagonist.

The spontaneously dispersible pharmaceutical composition is hereinafter also referred to as a “composition of the invention”. It is preferably a microemulsion preconcentrate.

Terms used in the specification have the following meanings:

“Active agent” as used herein means a 5-aryl-4(R)-arylcarbonylamino-pent-2-enoic acid amide substance P antagonist, such as those disclosed in WO 98/07694.

“Poorly water soluble” as used herein means having a solubility in water at 20° C. of less than 1%, for example 0.01% weight/volume, i.e. a “sparingly soluble to very slightly soluble drug” as described in Remington: The Science and Practice of Pharmacy, 19^(th) Edition, Ed. A. R. Gennaro, Mack Publishing Company, US, 1995, vol. 1, p 195.

“Bioavailable” as used herein with reference to a composition means the composition provides a maximum concentration of the active agent in that composition in a use environment that is at least 1.5 fold that of a control comprising an equivalent quantity of the undispersed drug.

“Spontaneously dispersible pharmaceutical composition” as used herein means a composition that contains an active agent herein defined and is capable of producing colloidal structures-when diluted with an aqueous medium, for example water, or in gastric juices. The colloidal structures can be solid or preferably liquid particles including droplets and nanoparticles. The spontaneously dispersible pharmaceutical composition is preferably a microemulsion preconcentrate.

“Microemulsion preconcentrate” as used herein means a composition which spontaneously forms a microemulsion in an aqueous medium, for example, in water, for example on dilution of 1:1 to 1:300, preferably 1:1 to 1:70, but especially 1:1 to 1:10 or in the gastric juices after oral application.

“Microemulsion” as used herein means a slightly opaque, opalescent, non-opaque or substantially non-opaque colloidal dispersion that is formed spontaneously or substantially spontaneously when its components are brought into contact with an aqueous medium. A microemulsion is thermodynamically stable and typically contains dispersed droplets of a mean diameter less than about 200 nm (2000 Å). Generally microemulsions comprise droplets or liquid nanoparticles that have a mean diameter of less than about 150 nm (1500 Å); typically less than 100 nm, generally greater than 10 nm, and they are stable over periods up to 24 hours.

Microemulsions offer greater ease of preparation due to spontaneous formation, thermodynamic stability, transparent and elegant appearance, increased drug loading, enhanced penetration through the biological membranes, increased bioavailability, and less inter- and intra-individual variability in drug pharmacokinetics than coarse emulsions. Further characteristics of microemulsions can be found in United Kingdom patent specification GB 2,222,770; Rosof, Progress in Surface and Membrane Science, 12, 405 et seq. Academic Press (1975); Friberg, Dispersion Science and Technology, 6 (3), 317 et seq. (1985); and Muller et al. Pharm. Ind., 50 (3), 370 et seq. (1988)].

Throughout this specification and in the claims that follow, unless the context requires otherwise, the word “comprise”, or variations such as “comprises” or “comprising”, will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps

In a second aspect the present invention provides a spontaneously dispersible pharmaceutical composition comprising a S-aryl-4(R)-arylcarbonylamino-pent-2-enoic acid amide substance P antagonist as an active agent, and a carrier medium comprising a lipophilic component, a surfactant, and optionally a hydrophilic component.

Preferably the spontaneously dispersible pharmaceutical composition is suitable for oral administration.

The 5-aryl-4(R)-arylcarbonylamino-pent-2-enoic acid amide substance P antagonist is poorly water soluble as herein defined. It has a water solubility of below 0.001%, e.g. 0.001 to 0.0001%.

The active agent is preferably used in free base form.

In a third aspect the present invention provides a microemulsion preconcentrate comprising a 5-aryl-4(R)-arylcarbonylamino-pent-2-enoic acid amide substance P antagonist.

In a fourth aspect the present invention provides a microemulsion preconcentrate comprising a 5-aryl-4(R)-arylcarbonylamino-pent-2-enoic acid amide substance P antagonist and a carrier medium that comprises a lipophilic component, a surfactant, and optionally a hydrophilic component.

The microemulsion preconcentrate preferably forms an o/w (oil-in-water) microemulsion when diluted with water.

Preferably the relative proportions of the lipophilic component(s), the hydrophilic component(s), and the surfactant(s) lie within the “Microemulsion” region on a standard three way plot graph. These phase diagrams, can be generated in a conventional manner as described in e.g. GB 2,222,770 or WO 96/13273.

In a fifth aspect the present invention provides a microemulsion comprising a 5-aryl-4(R)-arylcarbonylamino-pent-2-enoic acid amide substance P antagonist.

The microemulsion is preferably an o/w (oil-in-water) microemulsion.

In a sixth aspect the present invention provides a microemulsion comprising a 5-aryl-4(R)-arylcarbonylamino-pent-2-enoic acid amide substance P antagonist, a lipophilic component, a surfactant, water, and optionally a hydrophilic component.

The colloidal structures of the microemulsion form spontaneously or substantially spontaneously when the components of the composition of the invention are brought into contact with an aqueous medium, e.g. by simple shaking by hand for a short period of time, for example for 10 seconds. The compositions of the invention are thermodynamically stable, e.g. for at least 15 minutes or up to 4 hours, even to 24 hours. Typically, they contain dispersed structures, i.e. droplets or liquid nanoparticles of a mean diameter less than about 200 nm (2,000 Å), e.g. less than about 150 nm (1,500 Å), typically less than 100 nm (1,000 Å), generally greater than 10 nm (100 Å) as measured by standard light scattering techniques, e.g. using a MALVERN ZETASIZER 300™ particle characterising machine. Solid drug particles of mean diameter greater than 200 nm may also be present. The proportion of particles present may be temperature dependent.

The active agent is a neurokinin antagonist (NK antagonist) and is therefore capable of preventing disease symptoms that are caused inter alia by the activation of the NK1 receptor by substance P and the activation of the NK2 receptor by neurokinin A[=NKA]. The substance-P-antagonizing effects can be demonstrated, for example, as follows: in vitro, for example, the binding of ³H-substance P to the bovine retina in the radio receptor assay according to H. Bittiger, Ciba Foundation Symposium 91 (1982) 196-199, is inhibited with IC₅₀ values of from about 0.2 nM.

More specifically the active agent is a 5-aryl-4(R)-arylcarbonylamino-pent-2-enoic acid amide substance P antagonist. This class of compounds is described in WO 98/07694.

Preferred active agents, which are described in WO 98/07694, include:

-   (4R)-[N′-methyl-N′-(3,5-bistrifluoromethyl-benzoyl)-amino]-5-(1-methyl-indol-3-yl)-pent-2-enoic     acid N—[(R)-epsilon-caprolactam-3-yl]-amide, -   (4R)-[N′-methyl-N′-(3,5-bistrifluoromethyl-benzoyl)-amino]-5-(1-methyl-indol-3-yl)-pent-2-enoic     acid N-[(S)-epsilon-caprolactam-3-yl]-amide, -   (4R)-[N′-methyl-N′-(3,5-bistrifluoromethyl-benzoyl)-amino]-5-(1-methyl-indol-3-yl)-pent-2-enoic     acid N-cyclohexyl-amide, -   (4R)-[N′-methyl-N′-(3,5-bistrifluoromethyl-benzoyl)-amino]-5-(1-methyl-indol-3-yl)-2-methyl-pent-2-enoic     acid N-cyclohexyl-amide, -   (4R)-[N′-methyl-N′-(3,5-bistrifluoromethyl-benzoyl)-amino]-5-(1-methyl-indol-3-yl)-2-methyl-pent-2-enoic     acid N-[(R)-epsilon-caprolactam-3-yl]-amide, -   (4R)-[N′-methyl-N′-(3,5-bistrifluoromethyl-benzoyl)-amino]-5-(-methyl-indol-3-yl)-2-methyl-pent-2-enoic     acid N-[(S)-epsilon-caprolactam-3-yl]-amide, -   (4R)-(N′-methyl-N′-benzoyl-amino)-5-(1-methyl-indol-3-yl)-2-methyl-pent-2-enoic     acid N-[(R)-epsilon-caprolactam-3-yl]-amide, -   (4R)-[N′-methyl-N′-(3,5-bistrifluoromethyl-benzoyl)-amino]-5-(naphth-2-yl)-pent-2-enoic     acid N-[(R)-epsilon-caprolactam-3-yl]-amide, -   (4R)-(N′-methyl-N′-benzoyl)-amino-5-(naphth-2-yl)-pent-2-enoic acid     N-[(R)-epsilon-caprolactam-3-yl]-amide, -   (4R)-[N′-methyl-N′-(3,5-bistrifluoromethyl-benzoyl)-amino]-5-(naphth-2-yl)-2-methyl-pent-2-enoic     acid N-[(R)-epsilon-caprolactam-3-yl]-amide, -   (4R)-[N′-methyl-N′-(3,4,5-trimethoxy-benzoyl)-amino]-5-(naphth-2-yl)-2-methyl-pent-2-enoic     acid N-[(R)-epsilon-caprolactam-3-yl]-amide, -   (4R)-[N′-methyl-N′-(3,5-bistrifluoromethyl-benzoyl)-amino]-5-(naphth-2-yl)-2-methyl-pent-2-enoic     acid N-[(S)-epsilon-caprolactam-3-yl]-amide, -   (4R)-[N′-methyl-N′-(3,5-bistrifluoromethyl-benzoyl)-amino]-5-(naphth-2-yl)-2-methyl-pent-2-enoic     acid N-cyclohexyl-amide, -   (4R)-[N′-methyl-N′-(3,5-bistrifluoromethyl-benzoyl)-amino]-5-(1-methyl-indol-3-yl)-pent-2-enoic     acid N-[(S)-epsilon-caprolactam-3-yl]-amide, -   (4R)-[N′-methyl-N′-(3,5-bistrifluoromethyl-benzoyl)-amino]-4-(4-chlorobenzyl)-but-2-enoic     acid N-[(R)-epsilon-caprolactam-3-yl]-amide, -   (4R)-[N′-methyl-N′-(3,5-bistrifluoromethyl-benzoyl)-amino]-4-(4-chlorobenzyl)-but-2-enoic     acid N-[(5)-epsilon-caprolactam-3-yl]-amide, -   (4R)-[N′-methyl-N′-(3,5-bistrifluoromethyl-benzoyl)-amino]-4-(4-chlorobenzyl)-but-2-enoic     acid N-cyclohexyl-amide, -   (4R)-[N′-methyl-N′-(3,5-bistrifluoromethyl-benzoyl)-amino]-4-(3,4-dichlorobenzyl)-but-2-enoic     acid N-cyclohexyl-amide, -   (4R)-[N′-methyl-N′-(3,5-bistrifluoromethyl-benzoyl)-amino]-4-(3,4-difluorobenzyl)-but-2-enoic     acid N-cyclohexyl-amide, -   (4R)-[N′-methyl-N′-(3,5-bistrifluoromethyl-benzoyl)-amino]-5-(4-chlorophenyl)-2-methyl-pent-2-enoic     acid N-cyclohexylamide, -   (4R)-[N′-methyl-N′-(3,5-bistrifluoromethyl-benzoyl)-amino]-5-(4-chlorophenyl)-2-methyl-pent-2-enoic     acid N-[(R)-epsilon-caprolactam-3-yl]-amide, -   (4R)-[N′-methyl-N′-(3,5-bistrifluoromethyl-benzoyl)-amino]-4-(4-chlorobenzyl)-2-methyl-but-2-enoic     acid [(S)-epsilon-caprolactam-3-yl]-amide, -   (4R)-[N′-ethyl-N′-(3,5-bistrifluoromethyl-benzoyl)-amino]-5-(4-chlorophenyl)-pent-2-enoic     acid N-[(R)-epsilon-caprolactam-3-yl]-amide, -   (4R)-[N′-methyl-N′-(3,5-bistrifluoromethyl-benzoyl)-amino]-5-(4-chlorophenyl)-3-methyl-pent-2-enoic     acid N-cyclohexyl-amide, -   (4R)-[N′-methyl-N′-(3,5-bistrifluoromethyl-benzoyl)-amino]-4-(4-chlorobenzyl)-3-methyl-but-2-enoic     acid [(R)-epsilon-caprolactam-3-yl]-amide, -   (4R)-[N′-methyl-N′-(3,5-bistrifluoromethyl-benzoyl)-amino]-4-(4-chlorobenzyl)-but-2-enoic     acid N-[(R)-epsilon-caprolactam-3-yl]-amide, -   (4R)-4-[N′-methyl-N′-(3,5-bistrifluoromethyl-benzoyl)-amino]-4-(3,4-dichlorobenzyl)-but-2-enoic     acid N-[(R)-epsilon-caprolactam-3-yl]-amide, -   (4R)- and     (4S)-4-[N′-methyl-N′-(3,5-bistrifluoromethyl-benzoyl)-amino]-4-(3-fluoro-4-chlorobenzyl)-but-2-enoic     acid N-[(R)-epsilon-caprolactam-3-yl]-amide, -   (4R)- and     (4S)-4-[N′-methyl-N′-(3,5-bistrifluoromethyl-benzoyl)-amino]-4-(3,4-difluorobenzyl)-but-2-enoic     acid N-[(R)-epsilon-caprolactam-3-yl]-amide, -   (4R)- and     (4S)-4-[N′-methyl-N′-(3,5-bistrifluoromethyl-benzoyl)-amino]-4-(3,4-dibromobenzyl)-but-2-enoic     acid N-[(R)-epsilon-caprolactam-3-yl]-amide, -   (4R)- and     (4S)-4-[N′-methyl-N′-(3,5-bistrifluoromethyl-benzoyl)-amino]-4-(3,4,5-trifluorobenzyl)-     but-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide, -   (4R)- and     (4S)-4-[N′-methyl-N′-(3,5-bistrifluoromethyl-benzoyl)-amino]-4-(4-fluorobenzyl)-but-2-enoic     acid N-[(R)-epsilon-caprolactam-3-yl]-amide, -   (4R)- and     (4S)-[N′-(3,5-bistrifluoromethyl-benzoyl)-N′-methyl-amino]-5,5-diphenyl-pent-2-enoic     acid N-[(S)-epsilon-caprolactam-3-yl]-amide, -   (4S)-4-[N′-methyl-N′-(3,5-bistrifluoromethyl-benzoyl)amino]-4-(3,4-dichlorobenzyl)-but-2-enoic     acid N-[(R)-epsilon-caprolactam-3-yl]-amide, -   (4R)-4-[N′-methyl-N′-(3,5-bistrifluoromethylbenzoyl)amino]-4-(3,4-dichlorobenzyl)-but-2-enoic     acid N-[(S)-epsilon-caprolactam-3-yl]-amide, and -   (4S)-4-[N′-methyl-N′-(3,5-bistrifluoromethylbenzoyl)amino]-4-(3,4-dichlorobenzyl)-but-2-enoic     acid N-[(S)-epsilon-caprolactam-3-yl]-amide.

The especially preferred active agent is (4R)-4-[N′-methyl-N′-(3,5-bistrifluoro-methyl-benzoyl)amino]-4-(3,4-dichlorobenzyl)-but-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide, i.e. a compound of formula I

This compound is hereinafter referred to as Compound A.

The preferred and especially preferred active agents, in free or pharmaceutically acceptable salt form, may be prepared as described in international patent application WO 98/07694. As mentioned therein, they may be in the form of their hydrates and/or may include other solvents, for example solvents which may have been used for the crystallisation of compounds in solid form.

In accordance with the present invention the active agent may be present in an amount by weight of up to about 20% by weight of the composition of the invention, e.g. from about 0.05% by weight. The active agent is preferably present in an amount of 0.5 to 15% by weight of the composition, more preferably in an amount of 1.5 to 5% by weight of the composition.

The active agent is poorly water soluble so it is carried in a carrier medium.

In some embodiments of the compositions of the invention the carrier medium comprises a lipophilic component and a surfactant. In other embodiments the carrier medium comprises a lipophilic component, a hydrophilic component and a surfactant.

The lipophilic component comprises one or more lipophilic substances. The hydrophilic component comprises one or more hydrophilic substances. And the carrier medium can contain one or more surfactants.

The compositions of the invention can include a variety of additives including antioxidants, antimicrobial agents, enzyme inhibitors, stabilizers, preservatives, flavours, sweeteners and further components such as those described in Fiedler, H. P. “Lexikon der Hilfsstoffe für Pharmazie, Kosmetik und angrenzende Gebiete”, Editio Cantor, D-7960 Aulendorf, 4th revised and expanded edition (1996). These additives will conveniently be dissolved in the carrier medium.

The compositions of the invention include a lipophilic component or phase. The active agent may be contained in this component of the carrier medium.

The lipophilic component (when present) is preferably characterized by a low HLB value of less than 10, e.g. up to 8. Suitable lipophilic components include:

1) Glyceryl Mono-C₆-C₁₄-fatty Acid Esters

These are obtained esterifying glycerol with vegetable oil followed by molecular distillation. Monoglycerides suitable for use in the compositions of the invention include both symmetric (i.e. β-monoglycerides) as well as asymmetric monoglycerides (α-monoglycerides. They also include both uniform glycerides (in which the fatty acid constituent is composed primarily of a single fatty acid) as well as mixed glycerides (i.e. in which the fatty acid constituent is composed of various fatty acids) The fatty acid constituent may include both saturated and unsaturated fatty acids having a chain length of e.g. C₈-C₁₄. Particularly suitable are caprylic or lauric acid monoglycerides which are commercially available, e.g. under the trade names Imwitor® 308 or Imwitor® 312, respectively, from e.g. sasol. For example Imwitor® 308 comprises at least 80% monoglycerides and exhibits the following additional characterising data: free glycerol max 6%, acid value max. 3, saponification value 245-265, iodine value max. 1, water content max. 1%. Typically it comprises 1% free glycerol, 90% monoglycerides, 7% diglycerides, 1% triglycerides (H. Fiedler, loc. cit., volume 1, page 798). A further example is Capmul MCM C8 from Abitec Corporation.

2) Mixtures of mono- and di-glycerides of C₆-C₁₅ Fatty Acids

-   -   These include both symmetric (i.e. β-monoglycerides and         α,α¹-diglycerides) as well as asymmetric mono- and di-glycerides         (i.e. α-monoglycerides and α,β-diglycerides) and acetylated         derivatives thereof. They also include both uniform glycerides         (in which the fatty acid constituent is composed primarily of a         single fatty acid) as well as mixed glycerides (i.e. in which         the fatty acid constituent is composed of various fatty acids)         and any derivatives thereof with lactic or citric acid. The         fatty acid constituent may include both saturated and         unsaturated fatty acids having a chain length of from e.g.         C₈-C₁₀. Particularly suitable are mixed caprylic and capric acid         mono- and di-glycerides as commercially available, e.g. under         the trade name Imwitor® 742 or Imwitor 928, from e.g. sasol. For         example Imwitor® 742 comprises at least 45% monoglycerides and         exhibits the following additional characterising data: free         glycerol max. 2%, acid value max. 2, saponification value         250-280, iodine value max. 1, water max. 2% (H. Fiedler, loc.         cit., vol 1, page 798). Other suitable mixtures comprise         mono/diglycerides of caprylic/capric acid in glycerol as known         and commercially available under e.g. the trade name Capmul® MCM         from e.g. Abitec Corporation. Capmul® MCM exhibits the following         additional characterizing data: acid value 2.5 max., alpha-Mono         (as oleate) 80% min., free glycerol 2.5% max., iodine value 1         max., chain length distribution: caproic acid (C6) 3% max.,         caprylic acid (C8) 75% min., capric acid (C10) 10% min., lauric         acid (C12) 1.5% max., moisture (by Karl Fisher) 0.5% max.         (manufacturer information). Suitable examples of         mono-/di-glcyerides with additional derivatization with lactic         or citric acid are those marketed under the brand names of         Imwitor 375, 377 or 380 by sasol, Furthermore, the fatty acid         constituent may include both saturated and unsaturated fatty         acids having a chain length of from e.g. C₁₆-C₁₈. A suitable         example is Tegin® 0 (glyceryl oleate) exhibiting the following         additional characterising data: monoglyceride content 55-65%,         peroxide value max. 10, water content max. 1%, acid value max.         2, iodine value 70-76, saponification value 158-175, free         glycerol max. 2%, (manufacturer information).         3) Glyceryl di-C₆-C₁₈-fatty Acid Esters     -   These include symmetric (i.e. α,α¹-diglycerides) and asymmetric         diglycerides (i.e. α,β-diglycerides) and acetylated derivatives         thereof. They also include both uniform glycerides (in which the         fatty acid constituent is composed primarily of a single fatty         acid) as well as mixed glycerides (i.e. in which the fatty acid         constituent is composed of various fatty acids) and any         acetylated derivatives thereof. The fatty acid constituent can         include both saturated and unsaturated fatty acids having a         chain length of from C₆-C₁₈, e.g. C₆-C₁₆, e.g. C₅-C₁₀, e.g. C₈.         Particularly suitable is caprylic diglycerides, which is         commercially available, e.g. under the trade name Sunfat® GDC-S,         e.g. from Taiyo Kagaku Co., Ltd. Sunfat® GDC-S has an acid value         of about 0.3, a diglyceride content of about 78.8%, and a         monoester content of about 8.9.

4) Medium Chain Fatty Acid Triglyceride

-   -   These include triglycerides of saturated fatty acid having 6 to         12, e.g. 8 to 10, carbon atoms. Suitable medium chain fatty acid         triglycerides are those known and commercially available under         the trade names Acomed®, Myritol®, Captex®, Neobee®M 5 F,         Miglyol® 810, Miglyol® 812, Miglyol® 818, Mazol®, Sefsol®860,         Sefsol®870; Miglyol®812 being the most preferred. Miglyol®812 is         a fractionated coconut oil comprising caprylic-capric acid         triglycerides and having a molecular weight of about 520         Daltons. Fatty acid composition=C6 max. about 3%, C₈ about 50 to         65%, C₁₀ about 30 to 45%, C₁₂ max 5%; acid value about 0.1;         saponification value about 330 to 345; iodine value max 1.         Miglyol® 812 is available from Condea. Neobee® M 5 F is a         fractionated caprylic-capric acid triglyceride available from         coconut oil; acid value max. 0.2; saponification value about 335         to 360; iodine value max 0.5, water content max. 0.15%, D.²⁰         0.930-0.960, n_(D) ²⁰ 1.448-1.451 (manufacturer information).         Neobee® M 5 F is available from Stepan Europe. A further example         is Miglyol 829 containing additionally esters with succinic         acid.         5) Glyceryl mono-C₁₆-C₁₈-fatty Acid Esters     -   These are obtained esterifying glycerol with vegetable oil         followed by molecular distillation. Monoglycerides suitable for         use in the compositions of the invention include both symmetric         (i.e. β-monoglycerides) as well as asymmetric monoglycerides         (α-monoglycerides. They also include both uniform glycerides (in         which the fatty acid constituent is composed primarily of a         single fatty acid) as well as mixed glycerides (i.e. in which         the fatty acid constituent is composed of various fatty acids)         The fatty acid constituent may include both saturated and         unsaturated fatty acids having a chain length of from e.g.         C₁₆-C₁₈. Suitable examples include GMOrphic by Estman, Rylo MG20         distilled monoglyceride by Danisco Ingredients, or Monomuls         90-018 by Henkel. For example GMOrphic®-80 (glyceryl monooleate)         exhibits the following additional characterising data:         monoglyceride content min. 94%, C18:1 content 75% min., peroxide         value max. 2.5, C18:2+C18:3 max. 15%, C16:0+C18:0+C20:0 max.         10%, water max. 2%, acid value max. 3, iodine value 65-75,         saponification value 155-165, free glycerine max. 1%, hydroxyl         number 300-330 (manufacturer information).         6) Mixed mono-, di-, tri-glycerides     -   These include mixed mono-, di-, tri-glycerides that are         commercially available under the trade name Maisine® from         Gattefossé. They are transesterification products of corn oil         and glycerol. Such products are comprised predominantly of         linoleic and oleic acid mono-, di- and tri-glycerides together         with minor amounts of palmitic and stearic acid mono-, di- and         tri-glycerides (corn oil itself being comprised of ca. 56% by         weight linoleic acid, 30% oleic acid, ca. 10% palmitic and ca.         3% stearic acid constituents). Physical characteristics are:         free glycerol max 10%, monoglycerides ca. 40%, diglycerides ca.         40%, triglycerides ca. 10%, free oleic acid content ca. 1%.         Further physical characteristics are: acid value max. 2, iodine         value of 85-105, saponification value of 150-175, mineral acid         content=0. The fatty acid content for Maisine® is typically:         palmitic acid ca. 11%, stearic acid ca. 2.5%, oleic acid ca.         29%, linoleic acid ca. 56%, others ca. 1.5% (H. Fiedler, loc.         cit., volume 2, page 958; manufacturer information).

Mixed mono-, di-, tri-glycerides preferably comprise mixtures of C₈ to C₁₀ or C₁₂₋₂₀ fatty acid mono-, di- and tri-glycerides, especially mixed C₁₆-C₁₈ fatty acid mono-, di- and triglycerides. The fatty acid component of the mixed mono-, di- and tri-glycerides may comprise both saturated and unsaturated fatty acid residues. Preferably however they are predominantly comprised of unsaturated fatty acid residues; in particular C₁₈ unsaturated fatty acid residues. Suitably the mixed mono-, di-, tri-glycerides comprise at least 60%, preferably at least 75%, more preferably at least 85% by weight of a C₁₈ unsaturated fatty acid (for example linolenic, linoleic and oleic acid) mono-, di- and tri-glycerides. Suitably the mixed mono-, di-, tri-glycerides comprise less than 20%, for example about 15% or 10% by weight or less, saturated fatty acid (for example palmitic and stearic acid) mono-, di- and tri-glycerides. Mixed mono-, di-, tri-glycerides are preferably predominantly comprised of mono- and di-glycerides; for example mono- and di-glycerides comprise at least 50%, more preferably at least 70% based on the total weight of the lipophilic phase or component. More preferably, the mono- and di-glycerides comprise at least 75% (for example about 80% or 85% by weight of the lipophilic component. Preferably monoglycerides comprise from about 25 to about 50%, based on the total weight of the lipophilic component, of the mixed mono-, di-, tri-glycerides. More preferably from about 30 to about 40% (for example 35 to 40%) monoglycerides are present. Preferably diglycerides comprise from about 30 to about 60%, based on the total weight of the lipophilic component, of the mixed mono-, di-, tri-glycerides. More preferably from about 40 to about 55% (for example 48 to 50%) diglycerides are present. Triglycerides suitably comprise at least 5% but less than about 25%, based on the total weight of the lipophilic component, of the mixed mono-, di-, tri-glycerides. More preferably from about 7.5 to about 15% (for example from about 9 to 12%) triglycerides are present. Mixed mono-, di-, tri-glycerides may be prepared by admixture of individual mono-, di- or tri-glycerides in appropriate relative proportion. Conveniently however they comprise trans-esterification products of vegetable oils, for example almond oil, ground nut oil, olive oil, peach oil, palm oil or, preferably, corn oil, sunflower oil or safflower oil and most preferably corn oil, with glycerol. Such transesterification products are generally obtained as described in GB 2 257 359 or WO 94/09211. Preferably some of the glycerol is first removed to give a “substantially glycerol free batch” when soft gelatine capsules are to be made. Purified transesterification products of corn oil and glycerol provide particularly suitable mixed mono-, di-, and tri-glycerides hereinafter referred to as “refined oil” and produced according to procedures described in United Kingdom patent specification GB 2,257,359 or international patent publication WO 94/09211.

7) Acetylated Monoglycerides (C18)

-   -   These include Myvacet 9-45.

8) Propylene Glycol Monofatty Acid Esters

-   -   The fatty acid constituent may include both saturated and         unsaturated fatty acids having a chain length of from e.g.         C₈-C₁₂. Particularly suitable are propylene glycol mono ester of         caprylic and lauric acid as commercially available, e.g. under         the trade names Sefsol® 218, Capryol®90 or Lauroglycol®90, from         e.g. Nikko Chemicals Co., Ltd. or Gattefossé or Capmul PG-8 from         Abitec Corporation. For example Lauroglycol®90 exhibits the         following additional characterising data: acid value max. 8,         saponification value 200-220, iodine value max. 5, free         propylene glycol content max. 5%, monoester content min. 90%;         Sefsol® 218 exhibits the following additional characterising         data: acid value max. 5, hydroxy value 220-280 (H. Fiedler, loc.         cit., vol 2, page 906, manufacturer information).         9) Propylene glycol mono- and di- Fatty Acid Esters     -   These include Laroglycol FCC and Capryol PGMC.

10) Propylene Glycol Diesters

-   -   Propylene glycol di-fatty acid esters such as propylene glycol         dicaprylate (which is commercially available under the trade         name Miglyol® 840 from e.g. sasol; H. Fiedler, loc. cit., volume         2, page 1008) or Captex 200 from Abitec Corporation.

11) Propylene Glycol Monoacetate and Propylene Glycol Diacetate 12) Transesterified Ethoxylated Vegetable Oils

-   -   These include transesterified ethoxylated vegetable oils such as         those obtained by reacting various natural vegetable oils (for         example, maize oil, kernel oil, almond oil, ground nut oil,         olive oil, soybean oil, sunflower oil, safflower oil and palm         oil, or mixtures thereof) with polyethylene glycols that have an         average molecular weight of from 200 to 800, in the presence of         an appropriate catalyst. These procedures are described in         United States patent specification U.S. Pat. No. 3,288,824.         Transesterified ethoxylated corn oil is particularly preferred.

Transesterified ethoxylated vegetable oils are known and are commercially available under the trade name Labrafil® (H. Fiedler, loc. cit., vol 2, page 880). Examples are Labrafil® M 2125 CS (obtained from corn oil and having an acid value of less than about 2, a saponification value of 155 to 175, an HLB value of 3 to 4, and an iodine value of 90 to 110), and Labrafil® M 1944 CS (obtained from kernel oil and having an acid value of about 2, a saponification value of 145 to 175 and an iodine value of 60 to 90). Labrafil® M 2130 CS (which is a transesterification product of a C₁₂₋₁₈ glyceride and polyethylene glycol and which has a melting point of about 35 to 40° C., an acid value of less than about 2, a saponification value of 185 to 200 and an iodine value of less than about 3) may also be used. The preferred transesterified ethoxylated vegetable oil is Labrafil® M 2125 CS which can be obtained, for example, from Gattefossé, Saint-Priest Cedex, France.

13) Sorbitan Fatty Acid Esters

-   -   Such esters include e.g. sorbitan mono C₁₂₋₁₈ fatty acid esters,         or sorbitan tri C₁₂-18 fatty acid esters are commercially         available under the trade mark Span® from e.g. uniqema. An         especially preferred product of this class is e.g. Span® 20         (sorbitan monolaurate) or Span® 80 (sorbitan monooleate)         (Fiedler, loc. cit., 2, p. 1430; Handbook of Pharmaceutical         Excipients, loc. cit., page 473).

14) Esterified Compounds of Fatty Acid and Primary Alcohols

-   -   These include esterified compounds of fatty acid having 8 to 20         carbon atoms and primary alcohol having 2 to 3 carbon atoms, for         example, isopropyl myristate, isopropyl palmitate, ethyl         linoleate, ethyl oleate, ethylmyristate etc., with an esterified         compound of linoleic acid and ethanol being particularly         preferable, also isopropylmyristat and isopropylpalmitat.         15) Glycerol Triacetate or (1,2,3)-triacetin     -   This is obtained by esterifying glycerin with acetic anhydride.         Glycerol triacetate is commercially available as, e.g.         Priacetin® 1580 from Unichema International, or as Eastman™         Triacetin from Eastman, or from Courtaulds Chemicals Ltd.         Glycerol triacetate exhibits the following additional         characterising data: molecular weight 218,03, D.^(20,3)         1,159-1,163, n_(D) ²⁰ 1,430-1,434, water content max. 0.2%,         viscosity (25°) 17.4 mPa s, acid value max. 0.1, saponification         value of about 766-774, triacetin content 97% min. (H. Fiedler,         loc. cit., vol 2, page 1580; Handbook of Pharmaceutical         Excipients, loc. cit., page 534, manufacturer information).

16) Acetyl Triethyl Citrate

-   -   This is obtained by esterification of citric acid and ethanol,         followed by acetylation with acetic anhydride, respectively.         Acetyl triethyl citrate is commercially available, e.g. under         the trade name Citroflex® A-2, from e.g. Morflex Inc.

17) Tributylcitrate or Acetyl Tributyl Citrate 18) Polyglycerol Fatty Acid Esters

-   -   These have for example from 2 to 10, e.g. 6 glycerol units. The         fatty acid constituent can include both saturated and         unsaturated fatty acids having a chain length of from e.g.         C₈-C₁₈. Particularly suitable is e.g. Plurol Oleique CC497 from         Gattefossé, having a saponification value of 133-155 and a         saponification value of 196-244. Further suitable polyglycerol         fatty acid esters include diglyceryl monooleate (DGMO) and         Hexaglyn-5-O, as known and commercially available from e.g.         Nikko Chemicals Co., Ltd.

19) PEG-fatty Alcohol Ether

-   -   This includes Brij 30 polyoxyethylene(4) lauryl ether.

20) Fatty Alcohols and Fatty Acids

-   -   Fatty acids can be obtained by hydrolysing various animal and         vegetable fats or oils, such as olive oil, followed by         separation of the liquid acids. The fatty acid/alcohol         constituent can include both saturated and mono- or         di-unsaturated fatty acids/alcohols having a chain length of         from e.g. C₆-C₂₀. Particularly suitable are, e.g. oleic acid,         oleyl alcohol, linoleic acid, capric acid, caprylic acid,         caproic acid, tetradecanol, dodecanol, or decanol. Oleyl alcohol         is commercially available under the trade mark HD-Eutanol® V         from e.g. Henkel KGaA. Oleyl alcohol exhibits the following         additional characterising data: acid value max 0.1, hydroxy         value of about 210, iodine value of about 95, saponification         value max 1, D.²⁰ about 0.849, n_(D) ²⁰ 1.462, molecular weight         268, viscosity (20°) about 35 mPa s (manufacturer information).         Oleic acid exhibits the following additional characterising         data: molecular weight 282,47, D.²⁰ 0.895, n_(D) ²⁰ 1.45823,         acid value 195-202, iodine value 85-95, viscosity (25°) 26 mPa s         (H. Fiedler, loc. cit., volume 2, page 1112; “Handbook of         Pharmaceutical Excipients”, 2nd Edition, Editors A. Wade         and P. J. Weller (1994), Joint publication of American         Pharmaceutical Assoc., Washington, USA and The Pharmaceutical         Press, London, England, page 325).         21) Tocopherol and its Derivatives (e.g. Acetate)     -   These include Coviox T-70, Copherol 1250, Copherol F-1300,         Covitol 1360 and Covitol 1100.

22) Pharmaceutically Acceptable Oils

-   -   Alternatively the lipophilic component comprises e.g. a         pharmaceutically acceptable oil, preferably with an unsaturated         component such as a vegetable oil.

23) Alkylene Polyol Ethers or Esters

-   -   These include C₃₋₅alkylene triols, in particular glycerol,         ethers or esters. Suitable C₃₋₅alkylene triol ethers or esters         include mixed ethers or esters, i.e. components including other         ether or ester ingredients, for example transesterification         products of C₃₋₅alkylene triol esters with other mono-, di- or         poly-ols. Particularly suitable alkylene polyol ethers or esters         are mixed C₃₋₅alkylene triol/poly-(C₂₋₄alkylene) glycol fatty         acid esters, especially mixed glycerol/polyethylene- or         polypropylene-glycol fatty acid esters.

Especially suitable alkylene polyol ethers or esters include products obtainable by transesterification of glycerides, e.g. triglycerides, with poly-(C₂₋₄alkylene) glycols, e.g. poly-ethylene glycols and, optionally, glycerol. Such transesterification products are generally obtained by alcoholysis of glycerides, e.g. triglycerides, in the presence of a poly-(C₂₋₄alkylene) glycol, e.g. polyethylene glycol and, optionally, glycerol (i.e. to effect transesterification from the glyceride to the poly-alkylene glycol/glycerol component, i.e. via poly-alkylene glycolysis/glycerolysis). In general such reaction is effected by reacting the indicated components (glyceride, polyalkylene glycol and, optionally, glycerol) at elevated temperature under an inert atmosphere with continuous agitation.

Preferred glycerides are fatty acid triglycerides, e.g. (C₁₀₋₂₂fatty acid) triglycerides, including natural and hydrogenated oils, in particular vegetable oils. Suitable vegetable oils include, for example, olive, almond, peanut, coconut, palm, soybean and wheat germ oils and, in particular, natural or hydrogenated oils rich in (C₁₂₋₁₈fatty acid) ester residues. Preferred polyalkylene glycol materials are polyethylene glycols, in particular polyethylene glycols having a molecular weight of from ca. 500 to ca. 4,000, e.g. from ca. 1,000 to ca. 2,000.

Suitable alkylene polyol ethers or esters include mixtures of C₃₋₅alkylene triol esters, e.g. mono-, di- and tri-esters in variable relative amount, and poly(C₂₋₄alkylene) glycol mono- and di-esters, together with minor amounts of free C₃₋₅alkylene triol and free poly-(C₂₋₅alkylene) glycol. As hereinabove set forth, the preferred alkylene triol moiety is glyceryl; preferred polyalkylene glycol moieties include polyethylene glycol, in particular having a molecular weight of from ca. 500 to ca. 4,000; and preferred fatty acid moieties will be C₁₀₋₂₂fatty acid ester residues, in particular saturated C₁₀₋₂₂fatty acid ester residues.

Particularly suitable alkylene polyol ethers or esters include transesterification products of a natural or hydrogenated vegetable oil and a polyethylene glycol and, optionally, glycerol; or compositions comprising or consisting of glyceryl mono-, di- and tri-C₁₀₋₂₂fatty acid esters and polyethylene glycol mono- and di-C₁₀₋₂₂fatty esters (optionally together with, e.g. minor amounts of free glycerol and free polyethylene glycol).

Preferred vegetable oils, polyethylene glycols or polyethylene glycol moieties and fatty acid moieties in relation to the above definitions are as hereinbefore set forth.

Particularly suitable alkylene polyol ethers or esters as described above for use in the present invention include those commercially available under the trade name Gelucire® from e.g. Gattefossé, in particular the products:

-   a) Gelucire® 33/01, which has an m.p.=ca. 33-37° C. and a     saponification value of ca. 230-255; -   b) Gelucire® 39/01, m.p.=ca. 37.5-41.5° C., saponification v.=ca.     225-245; -   c) Gelucire® 43/01, m.p.=ca. 42-46° C., saponification v.=ca.     220-240;     -   Products (a) to (c) above all have an acid value of maximum         of 3. The compositions of the invention may include mixtures of         such ethers or esters.

24) Hydrocarbons

-   -   These include e.g. squalene, available from e.g. Nikko Chemicals         Co., Ltd.

25) Ethylene Glycol Esters

-   -   These include Monthyle® (ethylene glycol monostearate),         available from e.g. Gattefosse.

26) Pentaerythriol Fatty Acid Esters and Polyalkylene Glycol Ethers

-   -   These include, for example pentaerythrite-dioleate, -distearate,         -monolaurate, polyglycol ether, and -monostearate as well as         pentaerythrite-fatty acid esters (Fiedler, loc. cit., 2, p.         1158-1160, incorporated herein by reference).

Some of these, e.g. (1-3, 5-6, 8-9, 12-13, 19), display surfactant-like behaviour and may also be termed co-surfactants.

The lipophilic component (when present) preferably comprises 5 to 85% by weight of the composition of the invention, e.g. 10 to 85%; preferably 15 to 60% by weight, more preferably about 20 to about 40% by weight.

For those embodiments where the carrier medium comprises a hydrophilic component in addition to the lipophilic component and the surfactant the relative proportions of the lipophilic component(s), hydrophilic component(s) and the surfactant(s) lie within the “Microemulsion” region on a standard three way plot graph. The compositions of the invention may include a hydrophilic component or phase.

Suitable hydrophilic compounds include:

1) Polyethylene Glycol Glyceryl C₆-C₁₀ Fatty Acid Esters

-   -   The fatty acid ester may include mono and/or di and/or tri fatty         acid esters. It optionally includes both saturated and         unsaturated fatty acids having a chain length of from e.g.         C₈-C₁₀. The polyethylene glycols may have e.g. from 5 to 10         [CH₂—CH₂—O] units, e.g. 7 units. A particularly suitable fatty         acid ester is polyethylene glycol (7) glyceryl monococoate,         which is commercially available, e.g. under the trade name         Cetiol® HE, e.g. from Henkel KGaA. Cetiol® HE has a D. (20°) of         1.05, an acid value of less than 5, a saponification value of         about 95, a hydroxyl value of about 180 and an iodine value of         less than 5 (H. Fiedler, loc. cit., vol 1, page 337) or         Lipestrol E-810.

2) N-alkylpyrrolidone

-   -   Particularly suitable is, e.g. N-Methyl-2-pyrrolidone, e.g. as         commercially available under the trade name Pharmasolve™, from         e.g. International Specialty Products (ISP). N-methylpyrrolidone         exhibits the following additional characterising data: molecular         weight 99.1, D.²⁵ 1,027-1,028, purity (as area % by GC)         (including Methyl Isomers) 99.85% min (H. Fiedler, loc. cit.,         vol 2, page 1004, manufacturer information).

3) Benzyl Alcohol

-   -   This is commercially available from e.g. Merck or may be         obtained by distillation of benzyl chloride with potassium or         sodium carbonate. Benzyl alcohol exhibits the following         additional characterising data: molecular weight 108.14, D.         1.43-1.049, n_(D) 1.538-1.541. (H. Fiedler, loc. cit., vol 1,         page 238; Handbook of Pharmaceutical Excipients, loc. cit., page         35).

4) Triethyl Citrate

-   -   It is obtained esterifying citric acid and ethanol. Triethyl         citrate is commercially available, e.g. under the trade names         Citroflex® 2, or in a pharmaceutical grade under the name         TEC-PG/N, from e.g. Morflex Inc. Particularly suitable is         triethyl citrate which has molecular weight of 276.3, a specific         gravity of 1,135-1,139, a refractive index of 1,439-1,441, a         viscosity (25°) of 35.2 mPa s, assay (anhydrous basis)         99.0-100.5%, water max. 0.25% (Fiedler, H. P., loc. cit., vol 1,         page 371; “Handbook of Pharmaceutical Excipients”, loc. cit.,         page 540).

Other suitable hydrophilic compounds include transcutol (C₂Hs-[O—(CH₂)₂]₂—OH), glycofurol (also known as tetrahydrofurfuryl alcohol polyethylene glycol ether), 1,2-propylene glycol, dimethylisosorbide (Arlasolve), polyethylene glycol, triethylenglycol, ethylacetate, and ethyllactate.

The hydrophilic component may comprise 5 to 60% by weight of the composition of the invention, e.g. 10 to 50%; preferably 10 to 40% by weight, more preferably about 10 to about 30% by weight.

The hydrophilic component may comprise a mixture of two or more hydrophilic components.

The compositions of the invention may lower alkanols such as ethanol as a hydrophilic co-component. While the use of ethanol in the compositions is not essential, it has been found to be of particular advantage when the compositions are to be manufactured in soft gelatine, encapsulated form. This is because storage characteristics are improved, in particular the risk of active agent precipitation following encapsulation procedures is reduced. Thus the shelf life stability may be extended by employing ethanol or some other such co-component as an additional ingredient of the composition. The ethanol may comprise 0 to 60% by weight of the composition; preferably 5 to about 30% by weight and more preferably about 5 to 20% by weight.

The compositions of the present invention preferably contain one or more surfactants to reduce the interfacial tension thereby providing thermodynamic stability. Surfactants may be complex mixtures containing side products or unreacted starting products involved in the preparation thereof, e.g. surfactants made by polyoxyethylation may contain another side product, e.g. polyethylene glycol. The or each surfactant preferably has a hydrophilic-lipophilic balance (HLB) value of 8 to 17, especially 10 to 17. The HLB value is preferably the mean HLB value.

Suitable surfactants include:

1) Reaction Products of a Natural or Hydrogenated Castor Oil and Ethylene Oxide

-   -   The natural or hydrogenated castor oil may be reacted with         ethylene oxide in a molar ratio of from about 1:35 to about         1:60, with optional removal of the polyethylene-glycol component         from the products. Various such surfactants are commercially         available. Particularly suitable surfactants include         polyethyleneglycol-hydrogenated castor oils available under the         trade name Cremophor®; Cremophor® RH 40, which has a         saponification value of about 50 to 60, an acid value less than         about 1, a water content (Fischer) less than about 2%, an n_(D)         ⁶⁰ of about 1.453-1.457 and an HLB of about 14-16; and         Cremophor® RH 60, which has a saponification value of about         40-50, an acid value less than about 1, an iodine value of less         than about 1, a water content (Fischer) of about 4.5-5.5%, an         n_(D) ⁶⁰ of about 1.453-1.457 and an HLB of about 15 to 17.     -   An especially preferred product of this class is Cremophor®         RH40. Other useful products of this class are available under         the trade names Nikkol® (e.g. Nikkol® HCO-40 and HCO-60), Mapeg®         (e.g. Mapeg® CO-40 h), Incrocas® (e.g. Incrocas® 40), Tagat®         (for example polyoxyethylene-glycerol-fatty acid esters e.g.         Tagat® RH 40) and Simulsol OL-50 (PEG-40 castor oil, which has a         saponification value of about 55 to 65, an acid value of max. 2,         an iodine value of 25 to 35, a water content of max. 8%, and an         HLB of about 13, available from Seppic). These surfactants are         further described in Fiedler loc. cit.     -   Other suitable surfactants of this class include         polyethyleneglycol castor oils such as that available under the         trade name Cremophor® EL, which has a molecular weight (by steam         osmometry) of about 1630, a saponification value of about 65 to         70, an acid value of about 2, an iodine value of about 28 to 32         and an n_(D) ²⁵ of about 1.471.

2) Polyoxyethylene-sorbitan-fatty Acid Esters

-   -   These include mono- and tri-lauryl, palmityl, stearyl and oleyl         esters of the type known and commercially available under the         trade name Tween® (Fiedler, loc. cit. p. 1615 ff) from Uniqema         including the products:     -   Tween® 20 [polyoxyethylene(20)sorbitanmonolaurate],     -   Tween® 21 [polyoxyethylene(4)sorbitanmonolaurate],     -   Tween® 40 [polyoxyethylene(20)sorbitanmonopalmitate],     -   Tween® 60 [polyoxyethylene(20)sorbitanmonostearate],     -   Tween® 65 [polyoxyethylene(20)sorbitantristearate],     -   Tween® 80 [polyoxyethylene(20)sorbitanmonooleate],     -   Tween® 81 [polyoxyethylene(S)sorbitanmonooleate], and     -   Tween® 85 [polyoxyethylene(20)sorbitantrioleate].     -   Especially preferred products of this class are Tween® 20 and         Tween® 80.

3) Polyoxyethylene Fatty Acid Esters

-   -   These include polyoxyethylene stearic acid esters of the type         known and commercially available under the trade name Myrj® from         Uniqema (Fiedler, loc. cit., 2, p. 1042). An especially         preferred product of this class is Myrj® 52 having a D²⁶ of         about 1.1., a melting point of about 40 to 44° C., an HLB value         of about 16.9., an acid value of about 0 to 1 and a         saponification no. of about 25 to 35.

4) Polyoxyethylene-polyoxypropylene Co-polymers and Block Co-polymers or Poloxamers

-   -   These include the type known and commercially available under         the trade names Pluronic® and Emkalyx® (Fiedler, loc. cit.,         2, p. 1203). An especially preferred product of this class is         Pluronic® F68 (poloxamer 188) from BASF, having a melting point         of about 52° C. and a molecular weight of about 6800 to 8975. A         further preferred product of this class is Synperonic® PE L44         (poloxamer 124) from Uniqema.

5) Polyoxyethylene Mono Esters of a Saturated C₁₀ to C₂₂

-   -   These include C₁₁ substituted e.g. hydroxy fatty acid; e.g. 12         hydroxy stearic acid PEG ester, e.g. of PEG about e.g. 600-900         e.g. 660 Daltons MW, e.g. Solutol® HS 15 from BASF,         Ludwigshafen, Germany. According to the BASF technical leaflet         MEF 151E (1986) comprises about 70% polyethoxylated         12-hydroxystearate by weight and about 30% by weight         unesterified polyethylene glycol component. Solutol HS15 has a         hydrogenation value of 90 to 110, a saponification value of 53         to 63, an acid number of maximum 1, and a maximum water content         of 0.5% by weight.

6) Polyoxyethylene Alkyl Ethers

-   -   These include polyoxyethylene glycol ethers of C₁₂ to C₁₈         alcohols, e.g. Polyoxyl 2-, 10- or 20-cetyl ether or Polyoxyl         23-lauryl ether, or polyoxyl 20-oleyl ether, or Polyoxyl 2-,         10-, 20- or 100-stearyl ether, as known and commercially         available e.g. under the trade mark Brij® from Uniqema. An         especially preferred product of this class is e.g. Brij® 35         (Polyoxyl 23 lauryl ether) or Brij® 98 (Polyoxyl 20 oleyl ether)         (Fiedler, loc. cit., 1, pp. 259; Handbook of Pharmaceutical         Excipients, loc. cit., page 367). Similarly suitable products         include polyoxyethylene-polyoxypropylene-alkyl ethers, e.g.         polyoxyethylene-polyoxypropylene-ethers of C₁₂ to C₁₈ alcohols,         e.g. polyoxyethylen-20-polyoxypropy-lene-4-cetylether which is         known and commercially available under the trade mark Nikkol         PBC® 34, from e.g. Nikko Chemicals Co., Ltd. (Fiedler, loc.         cit., vol. 2, pp. 1239). Polyoxypropylene fatty acid ethers,         e.g. Acconon® E are also suitable.

7) Sodium Alkyl Sulfates and Sulfonates, and Sodium Alkyl Aryl Sulfonates

-   -   These include sodium lauryl sulfate, which is also known as         sodium dodecyl sulfate and commercially available, e.g. under         the trade name Texapon K12® from Henkel KGaA.

8) Water Soluble Tocopheryl Polyethylene Glycol Succinic Acid Esters (TPGS)

-   -   These include those with a polymerisation number ca 1000, e.g.         available from Eastman Fine Chemicals Kingsport, Tex., USA.

9) Polyglycerol Fatty Acid Esters

These include those with e.g. from 10 to 20, e.g. 10 glycerol units. The fatty acid constituent may include both saturated and unsaturated fatty acids having a chain length of from e.g. C₈-C₁₈. Particularly suitable is e.g. decaglycerylmonolaurat or decaglycerylmonomyristat, as known and commercially available under the trade mark Decaglyn® 1-L or Decaglyn® 1-M or Decaglyn 1-0, respectively, from e.g. Nikko Chemicals C., Ltd (Fiedler, loc. cit., vol. 2, pp. 1228).

10) Alkylene Polyol Ethers or Esters

-   -   These include C₃₋₅alkylene triols, in particular glycerol,         ethers or esters. Suitable C₃₋₅alkylene triol ethers or esters         include mixed ethers or esters, i.e. components including other         ether or ester ingredients, for example transesterification         products of C₃₋₅alkylene triol esters with other mono-, di- or         poly-ols. Particularly suitable alkylene polyol ethers or esters         are mixed C₃₋₅alkylene triol/poly-(C₂₋₄alkylene) glycol fatty         acid esters, especially mixed glycerol/polyethylene- or         polypropylene-glycol fatty acid esters.     -   Especially suitable alkylene polyol ethers or esters include         products obtainable by transesterification of glycerides, e.g.         triglycerides, with poly-(C₂₋₄alkylene) glycols, e.g.         poly-ethylene glycols and, optionally, glycerol.     -   Such transesterification products are generally obtained by         alcoholysis of glycerides, e.g. triglycerides, in the presence         of a poly-(C-_(2.4)alkylene) glycol, e.g. polyethylene glycol         and, optionally, glycerol (i.e. to effect transesterification         from the glyceride to the poly-alkylene glycol/glycerol         component, i.e. via poly-alkylene glycolysis/gly-cerolysis). In         general such reaction is effected by reacting the indicated         components (glyceride, polyalkylene glycol and, optionally,         glycerol) at elevated temperature under an inert atmosphere with         continuous agitation.     -   Preferred glycerides are fatty acid triglycerides, e.g.         (C₁₀₋₂₂fatty acid) triglycerides, including natural and         hydrogenated oils, in particular vegetable oils. Suitable         vegetable oils include, for example, olive, almond, peanut,         coconut, palm, soybean and wheat germ oils and, in particular,         natural or hydrogenated oils rich in (C₁₂₋₁₈fatty acid) ester         residues.     -   Preferred polyalkylene glycol materials are polyethylene         glycols, in particular polyethylene glycols having a molecular         weight of from ca. 500 to ca. 4,000, e.g. from ca. 1,000 to ca.         2,000.     -   Suitable alkylene polyol ethers or esters include mixtures of         C₃₋₅alkylene triol esters, e.g. mono-, di- and tri-esters in         variable relative amount, and poly(C₂₋₄alkylene) glycol mono-         and di-esters, together with minor amounts of free C₃₋₅alkylene         triol and free poly-(C₂₋₅alkylene) glycol. As hereinabove set         forth, the preferred alkylene triol moiety is glyceryl;         preferred polyalkylene glycol moieties include polyethylene         glycol, in particular having a molecular weight of from ca. 500         to ca. 4,000; and preferred fatty acid moieties will be         C₁₀₋₂₂fatty acid ester residues, in particular saturated         C₁₀₋₂₂fatty acid ester residues.     -   Particularly suitable alkylene polyol ethers or esters include         transesterification products of a natural or hydrogenated         vegetable oil and a polyethylene glycol and, optionally,         glycerol; or compositions comprising or consisting of glyceryl         mono-, di- and tri-C₁₀₋₂₂fatty acid esters and polyethylene         glycol mono- and di-C₁₀₋₂₂fatty esters (optionally together         with, e.g. minor amounts of free glycerol and free polyethylene         glycol).     -   Preferred vegetable oils, polyethylene glycols or polyethylene         glycol moieties and fatty acid moieties in relation to the above         definitions are as hereinbefore set forth.     -   Particularly suitable alkylene polyol ethers or esters as         described above for use in the present invention include those         commercially available under the trade name Gelucire® from e.g.         Gattefossé, in particular the products:     -   a) Gelucire® 44/14, m.p.=ca. 42.5-47.5° C., saponification         v.=ca. 79-93;     -   b) Gelucire® 50/13, m.p.=ca. 46-51° C., saponification v.=ca.         67-81;     -   Products (a) to (b) above all have an acid value of maximum of         2.     -   Alkylene polyol ethers or esters having an iodine value of         maximum 2 are generally preferred. The compositions of the         invention may include mixtures of such ethers or esters.     -   Gelucire® products are inert semi-solid waxy materials with         amphiphilic character. They are identified by their melting         point and their HLB value. Most Gelucire® grades are saturated         polyglycolised glycerides obtainable by polyglycolysis of         natural hydrogenated vegetable oils with polyethylene glycols.         They are composed of a mixture of mono-, di- and tri-glycerides         and mono- and di-fatty acid esters of polyethylene glycol.         Particularly suitable is Gelucire® 44/14 which has a nominal         melting point of 44° C. and an HLB of 14. It is obtained by         reacting hydrogenated palm kernels and/or hydrogenated palm oils         with polyethylene glycol 1500. It consists of approximately 20%         mono-, di- and triglycerides, 72% mono- and di-fatty acid esters         of polyethylene glycol 1500 and 8% of free polyethylene         glycol 1500. The fatty acid distribution for Gelucire® 44/14 is         as follows: 4-10 C₈, 3-9 C₁₀, 40-50 C₁₂, 14-24 C₁₄, 4-14 C₁₆,         5-15 C₁₈. Gelucire® 44/14 exhibits the following additional         characterising data: acid value of max. 2, iodine value of max.         2, saponification value of 79-93, hydroxyl value of 36-56,         peroxide value of max. 6, alkaline impurities max. 80, water         content max. 0.50, free glycerol content max. 3, monoglycerides         content 3.0-8.0. (H. Fiedler, loc. cit., vol 1, page 676;         manufacturer information).

11) Polyethylene Glycol Glyceryl Fatty Acid Esters

-   -   The fatty acid ester may include mono and/or di and/or tri fatty         acid ester. The fatty acid constituent may include both         saturated and unsaturated fatty acids having a chain length of         from e.g. C₁₂-C₁₈. The polyethylene glycols may have e.g. from         10 to 40 [CH₂—CH₂—O] units, e.g. 15 or 30 units. Particularly         suitable is polyethylene glycol (15) glyceryl monostearate which         is commercially available, e.g. under the trade name TGMS®-15,         e.g. from Nikko Chemicals Co., Ltd. Other suitable glyceryl         fatty acid esters include polyethylene glycol (30) glyceryl         monooleate which is commercially available, e.g. under the trade         name Tagat® 0, e.g. from Goldschmidt (H. Fiedler, loc. cit.,         vol. 2, p. 1502-1503), and Tagat® O (polytheylene glycol (20)         glycerol monooleate, as well as Tagat L (polytheylene         glycol (30) glycerol monolaurate) and Tagat L2 (polytheylene         glycol (20) glycerol monolaurate), all e.g. from Goldschmidt (H.         Fiedler, loc. cit., vol. 2, p. 1502-1503). A further suitable         polyethylene glycol glyceryl fatty acid ester is Tagat TO.

12) Sterols and Derivatives Thereof.

-   -   These include cholesterols and derivatives thereof, in         particular phytosterols, e.g. products comprising sitosterol,         campesterol or stigmasterol, and ethylene oxide adducts thereof,         for example soya sterols and derivatives thereof, e.g.         polyethylene glycol sterols, e.g. polyethylene glycol         phytosterols or polyethylene glycol soya sterols. The         polyethylene glycols may have e.g. from 10 to 40 [CH₂—CH₂—O]         units, e.g. 25 or 30 units. Particularly suitable is         polyethylene glycol (30) phytosterol which is commercially         available, e.g. under the trade name Nikkol BPS®-30, e.g. from         Nikko Chemicals Co., Ltd. Further suitable is polyethylene         glycol (25) soya sterol which is commercially available, e.g.         under the trade name Generol® 122 E 25, e.g. from Henkel (H.         Fiedler, loc. cit., vol. 1, p. 680).

13) Transesterified, Polyoxyethylated Caprylic-capric Acid Glycerides

-   -   These include those that are commercially available under the         trade name Labrasol® from e.g. Gattefossé. Labrasol® has an acid         value of max. 1, a saponification value of 90-110, and an iodine         value of max. 1 (H. Fiedler, loc. cit., vol 2, page 880).

14) Sugar Fatty Acid Esters

-   -   These include those of C₁₂-C₁₈ fatty acids, e.g. sucrose         monolaurate, e.g. Ryoto L-1695®, which is commercially available         from e.g. Mitsubishi-Kasei Food Corp., Tokyo, Japan.

15) PEG Sterol Ethers

-   -   These include those having, e.g. from 5 to 35 [CH₂—CH₂—O] units,         e.g. 20 to 30 units., e.g. Solulan® C24, which is commercially         available from e.g. Amerchol.

16) Dioctylsodiumsulfosuccinate

-   -   This is commercially available under the trade mark Aerosol OT®         from e.g. American Cyanamid Co. (Fiedler, loc. cit., 1, p. 118),         or di-[2-ethylhexyl]-succinate (Fiedler, loc. cit., volume 1, p.         487).

17) Phospholipids

-   -   These include in particular lecithins (Fiedler, loc. cit.,         volume 2, p. 910, 1184). Suitable lecithins include, in         particular, soya bean lecithins.

18) Salts of Fatty Acids, Fatty Acid Sulfates and Sulfonates

-   -   These include those of e.g. C₆-C₁₈, fatty acids, -fatty acid         sulfates and sulfonates, as known and commercially available         from e.g. Fluka.

19) Salts of Acylated Amino Acids

-   -   These include those of C₆-C₁₈, acylated amino acids, e.g. sodium         lauroyl sarcosinate, which is commercially available from e.g.         Fluka.         20) Medium or Long-chain Alkyl, e.g. C₆-C₁₈, Ammonium Salts     -   These include C₆-C₁₈ acylated amino acids e.g. cetyl trimethyl         ammonium bromide, which is commercially available from e.g. E.         Merck AG.

The surfactant may comprise 5 to 90% by weight of the composition of the invention; preferably 15 to 85% by weight, more preferably 20 to 60% by weight and even more preferably between about 35% and about 55% by weight.

Certain embodiments of the compositions of the invention include additives for example antioxidants, antimicrobial agents, enzyme inhibitors, stabilizers, preservatives, flavours, sweeteners and other components such as those described in Fiedler, H. P., loc. at.

Preferred antioxidants include ascorbyl palmitate, butyl hydroxy anisole (BHA), butyl hydroxy toluene (BHT) and tocopherols. The antioxidant α-tocopherol (vitamin E) is especially preferred.

These additives or ingredients may comprise about 0.05 to 5% by weight of the total weight of the composition. Antioxidants, antimicrobial agents, enzyme inhibitors, stabilizers or preservatives typically provide up to about 0.05 to 1% by weight based on the total weight of the composition. Sweetening or flavouring agents typically provide up to about 2.5 or 5% by weight based on the total weight of the composition.

The aforementioned additives can also include components that solidify a liquid micro-emulsion pre-concentrate (MEPC). These include solid polyethylene glycols (PEGs) and Gelucire™ products, preferably those such as like Gelucire™ 44/14 or Gelucire™ 50/13 that function as additional surfactants.

In a seventh aspect the invention provides a process for preparing a spontaneously dispersible pharmaceutical composition containing a S-aryl-4(R)-arylcarbonylamino-pent-2-enoic acid amide substance P antagonist as an active agent, which process comprises bringing the active agent and a carrier medium comprising (1) a lipophilic component, (2) a surfactant, and optionally (3) a hydrophilic component into intimate admixture.

The carrier medium can be prepared separately before bringing the active agent into intimate admixture with the carrier medium. Alternatively the two or more of the components of the carrier medium can be mixed together with the active agent.

The spontaneously dispersible pharmaceutical composition is preferably a microemulsion preconcentrate as herein defined.

The spontaneously dispersible pharmaceutical composition preferably spontaneously or substantially spontaneously forms an o/w (oil-in-water) emulsion, e.g. microemulsion, when diluted with an aqueous medium such as water to a dilution of 1:1 to 1:300, e.g. 1:1 to 1:70, especially 1:10 to 1:70, more especially e.g. 1:10, or in the gastric juices of a patient after oral application.

In an eighth aspect the invention provides a process for the preparing a microemulsion containing a S-aryl-4(R)-arylcarbonylamino-pent-2-enoic acid amide substance P antagonist as an active agent, which process comprises:

-   (i) bringing the active agent and a carrier comprising (1) a     lipophilic component, (2) a surfactant, and optionally (3) a     hydrophilic component into intimate admixture to form a     spontaneously dispersible pharmaceutical composition; and -   (ii) diluting the spontaneously dispersible pharmaceutical     composition in an aqueous medium to form the microemulsion.

As mentioned above, the active agent may be present in an amount by weight of up to about 20% by weight of the composition of the invention, e.g. from about 0.05% by weight. The active agent is preferably present in an amount of 0.5 to 15% by weight of the composition, more preferably in an amount of 1.5 to 5% by weight of the composition.

The lipophilic component preferably comprises 5 to 85% by weight of the composition of the invention, e.g. 10 to 85%; preferably 15 to 60% by weight, more preferably about 20 to about 40% by weight.

The hydrophilic component (when present) may comprise 5 to 60% by weight of the composition of the invention, e.g. 10 to 50%; preferably 10 to 40% by weight, more preferably about 10 to about 30% by weight. It may comprise a mixture of two or more hydrophilic components. The ratio of main hydrophilic component to hydrophilic co-component is typically from about 0.5:1 to about 2:1.

The surfactant may comprise 5 to 90% by weight of the composition of the invention; preferably 15 to 85% by weight, more preferably 20 to 60% by weight and even more preferably between about 35% and about 55% by weight.

The relative proportion of the active agent(s), the lipophilic component(s), the surfactant(s) and the hydrophilic component(s) (when present) preferably lie within the “Microemulsion” region on a standard three way plot graph. The compositions will therefore be of high stability that are capable, on addition to an aqueous medium, of providing microemulsions, for example having a mean particle size of <200 nm.

When the composition of the invention is a microemulsion preconcentrate it may be combined with water or an aqueous solvent medium to obtain an emulsion, for example a microemulsion. The emulsion or microemulsion may be administered enterally, for example orally, for example in the form of a drinkable solution.

When the composition of the invention is a microemulsion preconcentrate a unit dosage of the microemulsion preconcentrate is preferably used to fill orally administrable capsule shells. The capsule shells may be soft or hard capsule shells, for example made of gelatine. Each unit dosage will suitably contain from 0.1 to 100 mg active agent, for example 0.1 mg, 10 mg, 15 mg, 25 mg or 50 mg, preferably between 10 and 100 mg of the active agent, more preferably between 10 and 50 mg; for example 15, 20, 25, or 50 mg, more preferably between 5 and 20 mg, most preferably 5 or 10 mg. Such unit dosage forms are suitable for administration 1 to 5 times daily depending upon the particular purpose of therapy, the phase of therapy and the like. However, if desired, the compositions may be in drink solution form and may include water or any other aqueous system, e.g. fruit juice, milk, and the like, to provide e.g. colloidal systems, suitable for drinking, e.g. with a dilution of from about 1:10 to about 1:100.

The compositions of the invention, e.g. those in the examples hereinafter, may show good stability characteristics as indicated by standard stability trials, for example having a shelf life stability of up to one, two or three years, and even longer. One group of compositions of the invention may be of high stability that are capable, on addition to water, of providing aqueous microemulsions having an average particle size of <200 nm (2,000 Å), e.g. <150 nm (1,500 Å), e.g. <100 nm (1,000 Å).

The compositions of the invention exhibit especially advantageous properties when administered orally; for example in terms of consistency and high level of bioavailability obtained in standard bioavailability trials.

Pharmacokinetic parameters, for example drug substance absorption and measured for example as blood levels, also become surprisingly more predictable and problems in administration with erratic absorption may be eliminated or reduced. Additionally the pharmaceutical compositions are effective with biosurfactants or tenside materials, for example bile salts, being present in the gastro-intestinal tract. That is, the pharmaceutical compositions of the present invention are fully dispersible in aqueous systems comprising such natural tensides and thus capable of providing emulsion or microemulsion systems and/or particulate systems in situ which are stable. The function of the pharmaceutical compositions upon oral administration remain substantially independent of and/or unimpaired by the relative presence or absence of bile salts at any particular time or for any given individual. The compositions of this invention may also reduce variability in inter- and intra-patient dose response.

The utility of the compositions of the invention may be observed in standard clinical tests in, for example, known indications of active agent at dosages giving therapeutically effective active agent blood levels. Any increased bioavailability of the compositions of the invention may be observed in standard animal tests and in clinical trials.

The dose of the active agent in the compositions of the invention is of the same order as, or up to half, that used in known compositions containing the active agent. The compositions of the invention show activity at concentrations from about 0.1 mg to about 40 mg/day of active agent, preferably from about 0.1 mg to about 20 mg/day, e.g. most preferably from about 0.1 to about 1 mg/day of active agent for respiratory disease states.

The compositions of the invention are useful for the treatment of respiratory diseases, e.g. asthma and chronic bronchitis. For these indications, the appropriate dosage will, of course, vary depending upon, for example, the particular composition of the invention employed, the host, the mode of administration, and the nature and severity of the conditions being treated.

A typical dose for the active agent is from 0.1 to 1 mg/day for asthma and chronic bronchitis.

Thus in a ninth aspect the present invention provides a method of treatment of a subject suffering from a disorder treatable with a S-aryl-4(R)-arylcarbonylamino-pent-2-enoic acid amide substance P antagonist comprising administering a therapeutically effective amount of a pharmaceutical composition of the invention to a subject in need of such treatment.

The invention is illustrated by the following Examples.

EXAMPLES

In the following examples the pharmaceutically active agent is Compound A i.e. (4R)-4-[N′-methyl-N′-(3,5-bistrifluoro-methyl-benzoyl)amino]-4-(3,4-dichlorobenzyl)-but-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide.

Example 1 Filled Capsule (or Oral Solution)

The formulation contains:

Compound A 20 mg Cremophor RH 40 215 mg C8/C10 mono-/diglyceride 130 mg Triethylcitrate 85 mg Ethanol 50 mg

Example 2 Filled Capsule (or Oral Solution)

The formulation contains:

Compound A 10 mg Cremophor RH 40 219 mg Corn oil glycerides 174 mg Propyleneglycol 27 mg Ethanol 75 mg Tocopherol 0.5 mg

Example 3 Oral Solution

The formulation contains:

Compound A 10 mg/ml Cremophor RH 40 439 mg Corn oil glycerides 343 mg Propyleneglycol 88 mg Ethanol 99 mg Tocopherol 1.0 mg

The compositions of all three examples are prepared whereby the carrier components are mixed and the active ingredient is dissolved therein whilst stirring. The mixtures of the formulation of Examples 1 and 2 are filled into hard gelatine capsules and sealed using the Quali-Seal™ sealing technique.

Similarly, further examples are prepared as follows:

Excipients mg/1 g Cremophor RH40 423 Corn oil glycerides 253.8 PEG400 169.2 Ethanol 94 Compound A 60 Cremophor RH40 423 Corn oil glycerides 253.8 Triethylcitrate 169.2 Ethanol 94 Compound A 60 Cremophor RH40 418.5 C8/C10 mono-/diglycerides 251.1 PEG400 167.4 Ethanol 93 Compound A 70 Cremophor RH40 400.5 C8/C10 mono-/diglycerides 240.3 Propylene glycol 160.2 Ethanol 89 Compound A 110 Cremophor RH40 480 C8/C10 mono-/diglycerides 288 Triethylcitrat 192 Compound A 40 PEG-20 glyceryl oleat 380 C8/C10 mono-/diglycerides 285 Triethylcitrate 190 Ethanol 95 Compound A 50 Cremophor RH40 432 Propylene glycol monocaprylate 345.6 Span 80 86.4 Triethylcitrate 96 Compound A 40 Cremophor RH40 405 C8/C10 mono-/diglycerides 180 Propylene glycol monocaprylate 180 Ethanol 135 Compound A 100 Cremophor RH40 405 C8/C10 mono-/diglycerides 180 Propylene glycol monocaprylate 90 Triethylcitrate 90 Ethanol 135 Compound A 100 Cremophor EL 480 Capryol 90 288 Triethylcitrat 192 Compound A 40

No phase separation or precipitation observed for any of the above compositions which are clear for at least 4 hours.

2. Bioavailability

Bioavailability analysis of Example 1 in a dog study shows, that single peroral doses of 20 mg Compound A given as standard capsule formulation using micronized DS (formulation A) resulted in significantly lower plasma levels of Compound A (˜50%) than given as microemulsion (formulation B). For illustration of the data see table below and figure on page 1/1.

Form A: Powder in Capsule, Form B: Microemulsion C_(max)/dose AUC(0-48 h)/dose t_(max) [h] C_(max) [(ng/mL)/ AUC(0-48 h) [(ng/mL) · h/ f_(rel) Form Median [ng/mL] (mg/kg)] [(ng/mL) · h] (mg/kg)] (%) A 1.5 721 ± 545  385 ± 285 2622 ± 1584 1397 ± 811   46 ± 27 B 1 2109 ± 1136 1151 ± 666 6779 ± 4066 3683 ± 2335 100 ± 0

3. Embodiment

In general for our microemulsions the most preferred embodiment are soft gelatine capsules. This is due to the fact that a number of microemulsion excipients e.g. propylene glycol, are incompatible with hard gelatin capsules making them brittle. Soft gelatine capsules contain a large amount of softener and therefore compatibility is better. 

1-16. (canceled)
 17. A spontaneously dispersible pharmaceutical composition comprising a 5-aryl-4(R)-arylcarbonylamino-pent-2-enoic acid amide substance P antagonist.
 18. A composition according to claim 17 that includes a carrier medium that comprises a lipophilic component and a surfactant component.
 19. A composition as claimed in claim 18 where the 5-aryl-4(R)-aryl-carbonylamino-pent-2-enoic acid amide substance P antagonist is (4R)-4-[N′-methyl-N′-(3,5-bistrifluoro-methyl-benzoyl)amino]-4-(3,4-dichlorobenzyl)-but-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide.
 20. A pharmaceutical composition comprising (4R)-4-[N′-methyl-N′-(3,5-bistrifluoro-methyl-benzoyl) amino]-4-(3,4-dichlorobenzyl)-but-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide as active agent and a carrier medium comprising a lipophilic component and a surfactant, said composition being in an form that is suitable for oral administration.
 21. A composition as claimed in claim 20 wherein the carrier medium further comprises a hydrophilic component.
 22. A composition as claimed in claim 20 wherein the lipophilic component comprises C₈-C₁₀ fatty acid monoglycerides and diglycerides or a refined glycerol-transesterified corn oil.
 23. A composition as claimed in claim 20 wherein the surfactant comprises a polyethyleneglycol-hydrogenated castor oil.
 24. A composition as claimed in claim 21 wherein the hydrophilic component comprises propylene glycol.
 25. A spontaneously dispersible pharmaceutical composition as claimed in claim 18 that comprises about 0.05 to about 20% by weight of (4R)-4-[N′-methyl-N′-(3,5-bistrifluoro-methyl-benzoyl)amino]-4-(3,4-dichlorobenzyl)-but-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide, about 5 to about 85% by weight of a lipophilic component, about 5 to about 90% by weight of a surfactant, all weights based on the total composition.
 26. A composition as claimed in claim 25 that further comprises about 5 to about 60% by weight of a hydrophilic component, that weight based on the total composition.
 27. A composition as claimed in claim 17 in the form of a microemulsion preconcentrate.
 28. A composition as claimed in claim 20 in the form of a microemulsion preconcentrate.
 29. A composition as claimed in claim 17 in the form of a microemulsion.
 30. A composition as claimed in claim 20 in the form of a microemulsion.
 31. A composition as claimed in claim 20 in unit dosage form.
 32. A composition as claimed in claim 20 in soft or hard gelatin encapsulated form.
 33. A method of treating a subject suffering from a disorder treatable with a 5-aryl-4(R)-arylcarbonylamino-pent-2-enoic acid amide substance P antagonist comprising administering to that subject a therapeutically effective amount of a pharmaceutical composition as claimed in claim
 17. 34. A process for preparing a spontaneously dispersible pharmaceutical composition containing a 5-aryl-4(R)-arylcarbonylamino-pent-2-enoic acid amide substance P antagonist as an active agent, which process comprises bringing the active agent and a carrier medium comprising a lipophilic component and a surfactant into intimate admixture.
 35. A process for the preparing a microemulsion containing a 5-aryl-4(R)-arylcarbonyl-amino-pent-2-enoic acid amide substance P antagonist as an active agent, which process comprises the steps of: (i) bringing the active agent and a carrier comprising (1) a lipophilic component, (2) a surfactant, and (3) a hydrophilic component into intimate admixture to form a spontaneously dispersible pharmaceutical composition; and (ii) diluting the spontaneously dispersible pharmaceutical composition in an aqueous medium to form the microemulsion. 